Terbinafine 250mg Tablets
Terbinafine 1% w/w Cream
Terbinafine Hydrochloride BP 1%w/w
|10g of white semisolid cream filled in a collapsible lami tube.|
Terbinafine Hydrochloride BP 250mg
White, round, biconvex, uncoated tablet with plane surface on both sides.
Pregnancy: Category B
Nursing Mother: Terbinafine is excreted in breast milk and therefore mothers should not receive NAFIN treatment whilst breast-feeding.
Storage: Store at room temperature (below 25°C); Protect from light, heat and moisture; Keep out of reach of children.
Missed dose: Take the missed dose as soon as you remember; Skip the missed dose if it is almost time for your next scheduled dose; Do not take extra medicine to make up the missed dose.
Pharmacotherapeutic Group: Antifungal agent
Pharmacodynamic properties: NAFIN (Terbinafine) is an allylamine which has a broad spectrum of antifungal activity. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Terbinafine acts by inhibiting squalene epoxidase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. This inhibition also results in an accumulation of squalene.The resultant high concentration of squalene and decreased amount of ergosterol are both thought to contribute to terbinafine's antifungal activity.
Absorption: Absorbed well from the GI tract; Bioavailability (oral): 40%, Minimal absorption (topical); Peak plasma concentrations: 2 hr (oral).
Distribution: Distributed into stratum corneum of the skin, nail plate, hair (concentrations higher than plasma) and breastmilk; Protein-binding: Extensive.
Metabolism: Hepatic; converted to inactive metabolites.
Excretion: Via urine; 17-36 hr (plasma elimination half-life); up to 400 hr (terminal elimination half-life) in prolonged therapy.
Onychomycosis; Relieving itching, burning, cracking, and scaling associated with jock itch, athlete's foot, ringworm, and other fungal infections of the skin.
Topical:Apply the cream in the affected area once or twice daily. Duration of therapy: 1-2 wk to treat Tinea corporis and Tinea cruris; 1-wk course is for Tinea pedis; 2-wk course in cutaneous candidiasis and pityriasis versicolor
Oral: 250mg once daily; Duration of treatment:Infection of groin area, skin and feet: 2-4weeks; Onychomycosis: Fingernail: 6weeks; Toenail: 12weeks
Hypersensitivity; Severe renal or hepatic impairment; Lactation
Pre-existing liver or renal impairment; Pregnancy
ADVERSE DRUG REACTIONS
Topical: Burning, irritation; itching; blistering/ swelling/ oozing at the application site. Oral: Anorexia, nausea, abdominal pain, taste disturbances, diarrhoea, rash, urticaria. Potentially Fatal: Liver failure, Stevens-Johnson syndrome, neutropaenia.
Possible increase in levels in drugs metabolised by CYP450 2D6; Decreased terbinafine concentration with rifampicin; Increased terbinafine concentration with cimetidine
NAFIN 250: Each box contains 10 blister packs of 10 tablets per strip (inner catch cover per 2 strips).
NAFIN CREAM: Each tube contains 10g of cream.